Myochrysine (gold sodium thiomalate) Disease Interactions
There is 1 disease interaction with Myochrysine (gold sodium thiomalate):
Auranofin (Includes Myochrysine) ↔ bone marrow aplasia
Severe Potential Hazard, High plausibility. Applies to: Bone Marrow Depression/Low Blood Counts
The use of auranofin and other gold compounds is contraindicated in patients with a history of gold- induced bone marrow aplasia. Prior to gold compounds therapy, a complete blood count with a differential, platelet count, urinalysis, and renal and liver function tests should be performed. A complete blood count with a differential, platelet count, and urinalysis should be done at least monthly during therapy. Hematological warning signs of gold toxicity include a drop in hemoglobin, leukopenia (WBC < 4,000/mm3), granulocytopenia (< 1,500/mm3), and thrombocytopenia (<100,000/mm3).
- "Product Information. Ridaura (auranofin)." SmithKline Beecham, Philadelphia, PA.
- "Product Information. Solganal (aurothioglucose)." Schering Laboratories, Kenilworth, NJ.
- "Product Information. Myochrysine (gold sodium thiomaleate)." Merck & Co, Inc, West Point, PA.
Myochrysine (gold sodium thiomalate) drug interactions
There are 140 drug interactions with Myochrysine (gold sodium thiomalate)
More about Myochrysine (gold sodium thiomalate)
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No information available.|
Do not stop taking any medications without consulting your healthcare provider.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.